The clinical promise of immunotherapy in triple-negative breast cancer

References

• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• DawoodSBroglioKBuzdarAUHortobagyiGNGiordanoSHPrognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based reviewJ Clin Oncol2010281929819933921
   PubMed Web of Science ®Google Scholar
• CristofanilliMTurnerNCBondarenkoIFulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialLancet Oncol201617442543926947331
   PubMed Web of Science ®Google Scholar
• DiPippoAJPatelNKBarnettCMCyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and futurePharmaco-therapy2016366652667
   Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• LoiSTumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacyOncoimmunology201327e2472024073365
   PubMed Web of Science ®Google Scholar
• AdamsSGrayRJDemariaSPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199J Clin Oncol201432272959296625071121
   PubMed Web of Science ®Google Scholar
• García-TeijidoPCabalMLFernándezIPPérezYFTumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targetingClin Med Insights Oncol201610Suppl 1313927081325
   PubMedGoogle Scholar
• LoiSMichielsSSalgadoRTumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnn Oncol20142581544155024608200
   PubMed Web of Science ®Google Scholar
• AdamsSGoldsteinLJSparanoJADemariaSBadveSSTumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)Oncoimmunology201549e98593098593326405612
   PubMed Web of Science ®Google Scholar
• DenkertCvon MinckwitzGDarb-EsfahaniSAbstract S1-09: evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy – a metaanalysis of 3771 patientsCancer Res2017774 SupplementS109
   Google Scholar
• LoiSSirtaineNPietteFPrognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98J Clin Oncol201331786086723341518
   PubMed Web of Science ®Google Scholar
• DieciMVCriscitielloCGoubarAPrognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyAnn Oncol201425361161824401929
   PubMed Web of Science ®Google Scholar
• BorcherdingNKolbRGullicksrudJVikasPZhuYZhangWKeeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancerJ Mol Biol2018430142014202929800567
   PubMed Web of Science ®Google Scholar
• VinayakSGrayRJAdamsSAssociation of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105J Clin Oncol20173215_suppl1000
   Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• de VisserKECoussensLMThe inflammatory tumor microenvironment and its impact on cancer developmentContrib Microbiol20061311813716627962
   PubMedGoogle Scholar
• HagerlingCCasbonAJWerbZBalancing the innate immune system in tumor developmentTrends Cell Biol201525421422025444276
   PubMed Web of Science ®Google Scholar
• SharabiABNirschlCJKochelCMStereotactic radiation therapy augments antigen-specific pd-1-mediated antitumor immune responses via cross-presentation of tumor antigenCancer Immunol Res20153434535525527358
   PubMed Web of Science ®Google Scholar
• DemariaSKawashimaNYangAMImmune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancerClin Cancer Res2005112 Pt 172873415701862
   PubMed Web of Science ®Google Scholar
• Twyman-Saint VictorCRechAJMaityARadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature2015520754737337725754329
   PubMed Web of Science ®Google Scholar
• SharabiABLimMDeweeseTLDrakeCGRadiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergyLancet Oncol20151613e498e50926433823
   PubMed Web of Science ®Google Scholar
• TakahashiYYasuiTTamariKRadiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcomaPLoS One20171212e018969729253865
   PubMed Web of Science ®Google Scholar
• LangerCJGadgeelSMBorghaeiHCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyLancet Oncol201617111497150827745820
   PubMed Web of Science ®Google Scholar
• GandhiLRodríguez-AbreuDGadgeelSPembrolizumab plus chemotherapy in metastatic non-small-cell lung cancerN Engl J Med2018378222078209229658856
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• ChemnitzJMParryRVNicholsKEJuneCHRileyJLSHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activationJ Immunol2004173294595415240681
   PubMed Web of Science ®Google Scholar
• SheppardKAFitzLJLeeJMPD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCthetaFEBS Lett20045741–3374115358536
   PubMed Web of Science ®Google Scholar
• HargadonKMJohnsonCEWilliamsCJImmune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitorsInt Immunopharmacol201862293929990692
   PubMed Web of Science ®Google Scholar
• LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• LeDTDurhamJNSmithKNMismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience2017357634940941328596308
   PubMed Web of Science ®Google Scholar
• GhebehHMohammedSAl-OmairAThe B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factorsNeoplasia20068319019816611412
   PubMed Web of Science ®Google Scholar
• MuenstSSoysalSDGaoFObermannECOertliDGillandersWEThe presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancerBreast Cancer Res Treat2013139366767623756627
   PubMed Web of Science ®Google Scholar
• MuenstSSchaerliARGaoFExpression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Res Treat20141461152424842267
   PubMed Web of Science ®Google Scholar
• MittendorfEAPhilipsAVMeric-BernstamFPD-L1 expression in triple-negative breast cancerCancer Immunol Res20142436137024764583
   PubMed Web of Science ®Google Scholar
• BarrettMTAndersonKSLenkiewiczEGenomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancerOncotarget2015628264832649326317899
   PubMed Web of Science ®Google Scholar
• TaubeJMAndersRAYoungGDColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeSci Transl Med20124127127ra37
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• TaubeJMYoungGDMcMillerTLDifferential expression of immune-regulatory genes associated with PD-L1 display in melanoma: Implications for PD-1 pathway blockadeClin Cancer Res201521173969397625944800
   PubMed Web of Science ®Google Scholar
• TumehPCHarviewCLYearleyJHPD-1 blockade induces responses by inhibiting adaptive immune resistanceNature2014515752856857125428505
   PubMed Web of Science ®Google Scholar
• AnsellSMLesokhinAMBorrelloIPD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN Engl J Med2015372431131925482239
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med201537321627163926412456
   PubMed Web of Science ®Google Scholar
• PassigliaFBronteGBazanVPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisOncotarget2016715197381974726918451
   PubMedGoogle Scholar
• InoueHParkJHKiyotaniKIntratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanomaOncoimmunology201659e120450727757299
   PubMed Web of Science ®Google Scholar
• GandiniSMassiDMandalàMPD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysisCrit Rev Oncol Hematol2016100889826895815
   PubMed Web of Science ®Google Scholar
• SunWYLeeYKKooJSExpression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodiesJ Transl Med201614117327286842
   PubMedGoogle Scholar
• SabatierRFinettiPMamessierEPrognostic and predictive value of PDL1 expression in breast cancerOncotarget2015675449546425669979
   PubMedGoogle Scholar
• AdamsSSchmidPRugoHSPhase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort AJ Clin Oncol20173515_suppl1008
   Google Scholar
• DirixLTakacsINikolinakosPAvelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trialSan Antonio Breast Cancer Symposium2014S14
   Google Scholar
• NandaRChowLQDeesECPembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 studyJ Clin Oncol201634212460246727138582
   PubMed Web of Science ®Google Scholar
• SchmidPAtezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analysesAACR Proceedings2017 #2986
   Google Scholar
• AdamsSLoiSToppmeyerDPhase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort BJ Clin Oncol20173515_suppl1088
   Google Scholar
• NandaRLiuMCYauCPembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2J Clin Oncol20173515_suppl50628029304
   PubMed Web of Science ®Google Scholar
• SchmidPParkYHMuñoz-CouseloEPembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173PASCO20173515_suppl556
   Google Scholar
• NolanESavasPPolicheniANCombined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancerSci Transl Med20179393eaal492228592566
   PubMed Web of Science ®Google Scholar
• KonstantinopoulosPAWaggonerSEVidalGATOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—results from ROC cohortJ Clin Oncol20183615_suppl106
   Web of Science ®Google Scholar
• SandhuSKSchelmanWRWildingGThe poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialLancet Oncol201314988289223810788
   PubMed Web of Science ®Google Scholar
• EmensLBraitehFCassierPInhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancerSan Antonio Breast Cancer Symposium2014PD1PD16
   Google Scholar
• LoiblSUntchMBurchardiNRandomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC)J Clin Oncol20183615_suppl104
   Google Scholar
• LiCWLimSOChungEMEradication of triple-negative breast cancer cells by targeting glycosylated PD-L1Cancer Cell2018332e10:187201
   Web of Science ®Google Scholar
• WingKOnishiYPrieto-MartinPCTLA-4 control over Foxp3+ regulatory T cell functionScience2008322589927127518845758
   PubMed Web of Science ®Google Scholar
• SelbyMJEngelhardtJJQuigleyMAnti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intra-tumoral regulatory T cellsCancer Immunol Res201311324224777248
   PubMed Web of Science ®Google Scholar
• Arce VargasFFurnessAJSLitchfieldKFc effector function contributes to the activity of human anti-CTLA-4 antibodiesCancer Cell201833464966329576375
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• HellmannMDCiuleanuTEPluzanskiANivolumab plus ipilimumab in lung cancer with a high tumor mutational burdenN Engl J Med2018378222093210429658845
   PubMed Web of Science ®Google Scholar
• BrignoneCGutierrezMMeftiFFirst-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activityJ Transl Med201087120653948
   PubMed Web of Science ®Google Scholar
• HongDSSchoffskiPCalvoAPhase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignanciesJ Clin Oncol20183615_suppl3012
   Google Scholar
• PiconeseSValzasinaBColomboMPOX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejectionJ Exp Med2008205482583918362171
   PubMed Web of Science ®Google Scholar
• LinchSNMcNamaraMJRedmondWLOX40 agonists and combination immunotherapy: putting the pedal to the metalFront Oncol201553425763356
   PubMed Web of Science ®Google Scholar
• DiabAHurwitzMEChoDCNKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: preliminary phase 1/2 results of PIVOTJ Clin Oncol201836300615_suppl3006
   Google Scholar
• CalvoAJoensuuHSebastianMPhase Ib/II study of lacnotu-zumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumorsJ Clin Oncol201836301415_suppl3014
   Google Scholar
• KwonEDDrakeCGScherHICA184-043 InvestigatorsIpilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialLancet Oncol201415770071224831977
   PubMed Web of Science ®Google Scholar
• GoldenEBDemariaSSchiffPBChachouaAFormentiSCAn abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancerCancer Immunol Res20131636537224563870
   PubMed Web of Science ®Google Scholar
• KokMVoorwerkLHorlingsHAdaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational dataJ Clin Oncol20183615_suppl1012
   Web of Science ®Google Scholar
• MilesDRochéHMartinMTheratope® Study GroupPhase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancerOncologist20111681092110021572124
   PubMed Web of Science ®Google Scholar
• IbrahimNKMurrayJLZhouDSurvival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trialJ Cancer20134757758423983823
   PubMed Web of Science ®Google Scholar
• MeleroIGaudernackGGerritsenWTherapeutic vaccines for cancer: an overview of clinical trialsNat Rev Clin Oncol201411950952425001465
   PubMed Web of Science ®Google Scholar
• ŁukszaMRiazNMakarovVA neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyNature2017551768151752029132144
   PubMed Web of Science ®Google Scholar
• OttPAHuZKeskinDBAn immunogenic personal neoantigen vaccine for patients with melanomaNature2017547766221722128678778
   PubMed Web of Science ®Google Scholar
• LinnemannCvan BuurenMMBiesLHigh-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanomaNat Med2015211818525531942
   PubMed Web of Science ®Google Scholar
• SahinUDerhovanessianEMillerMPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerNature2017547766222222628678784
   PubMed Web of Science ®Google Scholar
• StrønenEToebesMKeldermanSTargeting of cancer neo-antigens with donor-derived T cell receptor repertoiresScience201635262911337134127198675
   PubMed Web of Science ®Google Scholar
• VermorkenJBClaessenAMvan TinterenHActive specific immunotherapy for stage II and stage III human colon cancer: a randomised trialLancet199935391503453509950438
   PubMed Web of Science ®Google Scholar
• SmallEDemkowTGerritsenWRA phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)2009 Genitourinary Cancers Symposium200907
   Google Scholar
• SchusterSJNeelapuSSGauseBLVaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaJ Clin Oncol201129202787279421632504
   PubMed Web of Science ®Google Scholar
• GiacconeGBazhenovaLANemunaitisJA phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC)Eur J Cancer201349S2S3
   Web of Science ®Google Scholar
• SchollSSquibanPBizouarneNMetastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2J Biomed Biotechnol20032003319420112975534
   PubMedGoogle Scholar
• ChungVMKosFHardwickNA phase 1 study of p53MVA vaccine in combination with pembrolizumabJ Clin Oncol2018365_suppl206
   Web of Science ®Google Scholar
• KimataHImaiTKikumoriTPilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancerAnn Surg Oncol20061381078108416865590
   PubMed Web of Science ®Google Scholar
• SahinTTKasuyaHNomuraNImpact of novel oncolytic virus HF10 on cellular components of the tumor microenvironment in patients with recurrent breast cancerCancer Gene Ther201219422923722193629
   PubMed Web of Science ®Google Scholar